The abstract is read at the publisher; the summary is JClub's.
Lysosomal biogenesis sensing temporally precedes disease-associated microglia reprogramming and shows evolutionarily conserved coupling, with amplification scaling from +0.252 in acute injury to +0.072 in decades-long human AD progression.
- Why it matters: The intracellular logic linking lysosomal signaling to DAM state conversion in vivo is unclear, especially how phagocytic/lysosomal load quantitatively relates to disease timing across models and human cohorts.
- What they did: Using a unit-corrected framework to avoid pseudo-replication, the authors integrated six murine transcriptomic datasets and three human neurodegenerative cohorts (>320,000 microglial nuclei), plus AD GWAS (MAGMA), and tested Trem2-knockout models.
- The result: MITF and TFE3 transcripts track DAM activation while TFEB mRNA does not; AD genetic risk is anchored downstream at APOE, and Trem2 loss retains about half the coupling amplification even as mature DAM collapses.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.